Product Information
NORA-BE TABLET is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $0.0924 per EA under NDC 00480347516. Its NADAC has been published 136 times since Feb 28, 2024.
FDA first approved this application before 1982. Its Orange Book therapeutic-equivalence code is AB1 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
.35 mg/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00480347516
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
NORETHINDRONEApproval Type
Authorized Generic (NDA)
FDA Application
NDA017060FDA Approved
Before 1982
TE Code
AB1
On Market Since
12/1/2023
Pharmacological Classes
Price Statistics
The NADAC for NORA-BE TABLET has been published 136 times since Feb 28, 2024, and over the history we have for it it has declined 16.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0924 per EA |
|---|---|
| All-time high | $0.1170 (Apr 10, 2024) |
| All-time low | $0.0691 (Nov 20, 2024) |
| 52-week high | $0.0945 |
| 52-week low | $0.0849 |
| Median price | $0.0906 |
| Average price | $0.0916 |
| Largest weekly change | +43.4% (Aug 21, 2024) |
| Weeks tracked | 136 |
| Tracking since | Feb 28, 2024 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 2% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Norethindrone market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Progestin class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of NORA-BE TABLET?
The current National Average Drug Acquisition Cost (NADAC) for NORA-BE TABLET, manufactured by Teva Pharmaceuticals USA Inc., is $0.0924 per EA (NDC 00480347516), effective Sep 30, 2026.
How has the price of NORA-BE TABLET changed over time?
Over the history we have for it, the NADAC for NORA-BE TABLET has declined 16.4%. It has been tracked across 136 weekly CMS publications since Feb 28, 2024.
What are the highest and lowest recorded NADAC prices for NORA-BE TABLET?
Since Feb 28, 2024, the NADAC for NORA-BE TABLET has ranged from a low of $0.0691 (Nov 20, 2024) to a high of $0.1170 (Apr 10, 2024), with a median of $0.0906 per EA.
Are there cheaper alternatives to NORA-BE TABLET?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, NORETHINDRONE 0.35 MG TABLET, is $0.0906 per EA — about 2% below NORA-BE TABLET.
Who manufactures NORA-BE TABLET?
NORA-BE TABLET (NDC 00480347516) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.